粪便微生物移植胶囊在肝性脑病中的安全性:一项1期随机安慰剂对照试验
在弗吉尼亚开展的1期随机单盲安慰剂对照试验中,20例接受利福昔明/乳果糖标准治疗且MELD<17的复发性肝性脑病肝硬化患者按1:1随机接受15粒粪便微生物移植胶囊或安慰剂。FMT胶囊安全且耐受良好,与十二指肠黏膜多样性改善、菌群失调改善、抗菌肽表达增加、血清LBP降低及EncephalApp表现改善相关,但需进一步研究证明疗效。
要点
- 复发性肝性脑病肝硬化患者口服15粒FMT胶囊安全且耐受良好。
- FMT后十二指肠黏膜多样性增加,Ruminococcaceae和Bifidobacteriaceae升高。
- FMT后EncephalApp表现改善(P=0.02),但需进一步研究证明疗效。
核心结论
- 在这项1期研究中,口服FMT胶囊在肝硬化和复发性肝性脑病患者中安全且耐受良好。
- FMT与十二指肠黏膜多样性改善、菌群失调改善、抗菌肽表达增加、LBP降低及EncephalApp表现改善相关。
- 需要进一步研究证明疗效。
研究设计与样本
- 在弗吉尼亚开展的1期随机、单盲、安慰剂对照临床试验。
- 接受标准治疗(利福昔明/乳果糖)且MELD<17的复发性肝性脑病肝硬化患者按1:1随机接受15粒FMT胶囊或安慰剂,供体为富含Lachnospiraceae和Ruminococcaceae的单一供体。
- 采用内镜下十二指肠和乙状结肠活检、粪便分析、认知评估、血清LBP及十二指肠抗菌肽表达检测,临床随访至5个月。
主要发现
- 20例接受乳果糖/利福昔明治疗的患者按1:1随机分组,基线MELD评分相似(9.6 vs 10.2),研究结束时也相似(10.2 vs 10.5)。
- 安慰剂组6例患者需要住院,FMT组1例,判定与FMT无关。
- 两组感染/肝性脑病发作次数相似,基线各组织微生物多样性组间相似。
- FMT后十二指肠黏膜多样性增加(P=0.01),Ruminococcaceae和Bifidobacteriaceae升高,Streptococcaceae和Veillonellaceae降低。
- FMT后乙状结肠(P=0.04)和粪便(P=0.05)中Veillonellaceae减少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatic encephalopathy (HE) can cause major morbidity despite standard of care (SOC; rifaximin/lactulose). Fecal microbial transplant (FMT) enemas postantibiotics are safe, but the effect of FMT without antibiotics using the capsular route requires investigation. The aim of this work was to determine the safety, tolerability, and impact on mucosal/stool microbiota and brain function in HE after capsular FMT in a randomized, single-blind, placebo-controlled clinical trial in Virginia. Patients with cirrhosis with recurrent HE with MELD (Model for End-Stage Liver Disease) <17 on SOC were randomized 1:1 into receiving 15 FMT capsules versus placebo from a single donor enriched in Lachnospiraceae and Ruminococcaceae. Endoscopies with duodenal and sigmoid biopsies, stool analysis, cognition, serum lipopolysaccharide-binding protein (LBP), and duodenal antimicrobial peptide (AMP) expression at baseline were used. Clinical follow-up with SOC maintenance was performed until 5 months. FMT-assigned patients underwent repeat endoscopies 4 weeks postenrollment. Twenty subjects on lactulose/rifaximin were randomized 1:1. MELD score was similar at baseline (9.6 vs. 10.2) and study end (10.2 vs. 10.5). Six patients in the placebo group required hospitalizations compared to 1 in FMT, which was deemed unrelated to FMT. Infection/HE episodes were similar between groups. Baseline microbial diversity was similar in all tissues between groups. Post-FMT, duodenal mucosal diversity (P = 0.01) increased with higher Ruminococcaceae and Bifidobacteriaceae and lower Streptococcaceae and Veillonellaceae. Reduction in Veillonellaceae were noted post-FMT in sigmoid (P = 0.04) and stool (P = 0.05). Duodenal E-cadherin (P = 0.03) and defensin alpha 5 (P = 0.03) increased whereas interleukin-6 (P = 0.02) and serum LBP (P = 0.009) reduced post-FMT. EncephalApp performance improved post-FMT only (P = 0.02). Conclusion: In this phase 1 study, oral FMT capsules are safe and well tolerated in patients with cirrhosis and recurrent HE. FMT was associated with improved duodenal mucosal diversity, dysbiosis, and AMP expression, reduced LBP, and improved EncephalApp performance. Further studies are needed to prove efficacy.
引用
- Bajaj JS, Salzman NH, Acharya C, et al. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. Hepatology. 2019. PMID: 31038755. doi:10.1002/hep.30690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。